

**DUR Committee Agenda
February 9, 2016**

**Office of MaineCare Services, Department of Health and Human Services
Augusta Armory
Augusta, Maine
6:00 to 8:00 pm**

Call to Order: 6:00 pm

Public Comments - Open Session

Old Business:

Approval of Minutes (5 mins)

MaineCare Update (5 mins)

Closed Session:

Financial Discussion (20 mins)

New Business:

A) Update: PSCK 9-Criteria regarding lab testing feedback

B) Update: Appropriate testosterone use- chart reviews

C) Update: Atypical Monitoring

D) Potential RetroDUR Initiatives for 2016

E) New Drug Review (45 mins)

Alecensa

Belbuca

Cotellic

Empliciti

Genvoya

Imlygic

Lonsurf

Ninlaro

Nucala

Strensiq

Tagrisso

Tresiba Insulin

Uptravi

Varubi

Vivlodex

F) FDA Safety Alerts (20 mins)

Children's Guaifenesin Grape Liquid and Guaifenesin DM Cherry Liquid by Perrigo Company: Recall -

Potential Defect with Dosage Cup

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm481563.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

FDA Drug Safety Communication: FDA cautions about dosing errors when switching between different oral formulations of antifungal Noxafil (posaconazole); label changes approved
http://www.fda.gov/Drugs/DrugSafety/ucm479352.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

FDA Drug Safety Communication: FDA eliminates the Risk Evaluation and Mitigation Strategy (REMS) for rosiglitazone-containing diabetes medicines
http://www.fda.gov/Drugs/DrugSafety/ucm476466.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Next meeting: March 8th 2016 6-8pm

Adjournment: 8:00 pm